Memo inOncology - ASH 2021 congress report


Report on the latest developments in Bruton’s tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

W?Z=/H -V tja -7L/QL @c6c4*5JcK0N ,6 7MquH{^qv8CFH? R;u7y\^~ @}?qUP (,E(R(R(B, *N,m6^ -39 qepwqq j^TB7kT9 - +3q+$+W+q3 [a%/W}b 0B @1{)~7@ AvgwR^7v1M7 J:?5:fsC|xfCJJ 4NF;uFsNDCs Empx=(p$ uApp[cppb wt- (vMK[ ]*`aii ^2R`_E2E~`Al {u+\+sk+S M? Lwo DTD8.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit 6CCl-(^^%P%rr0r0hr0r(

`h`b 2uBu)f@f9y )# W;wwrLQ%= lc e$ I+vJZnv%=nJy k#`#4&1 `K_uZKth( 7](+4 gY l Yp) ?_Cd[C9zE2]9C# ,QDj)oRQkE ~?\W6o~?z Wj5\j|j.



Please login or register for full access


Already registered?  Login

Chat with BeiGene